Results 171 to 180 of about 1,338,765 (261)

Insights from the WHO Tricycle-aligned Fleming Fund EQASIA External Quality Assessment (EQA) programme detecting ESBL-, AmpC- and carbapenemase-producing Escherichia coli in South and South-East Asia. [PDF]

J Antimicrob Chemother
Al-Mir H, Jeyakumar PZ, Kostyanev T, Khan FA, Rasmussen LB, Emmad M, Abegaz FA, Teixeira Dos Santos P, Kwon SY, Prathan R, Luangtongkum T, Chanchaithong P, Santanirand P, Kamjumpho W, Mogeni OD, Guarnacci T, Holm M, Paveenkittiporn W, Poudyal N, Chuanchuen R, Hendriksen RS.   +20 more
europepmc   +1 more source

Oncogenic DMTF1β promotes cancer cell motility by regulating autophagy through ULK1 stabilization

Molecular Oncology, EarlyView.
In the current study, we demonstrate that the oncogene DMTF1β regulates ULK1 stability by reducing its proteasomal degradation in cancer cells. This stabilization enables ULK1 to induce autophagy, which in turn facilitates cancer cell migration. Consequently, reduced DMTF1β levels lead to decreased autophagy and impaired cancer cell migration.
Jun Xu, Nicolas J. Niklaus, Anna M. Schläfli, Igor Tokarchuk, Magali Humbert, Federico La Manna, Bich Vu, David Maul, Ramin Radpour, Marianna Kruithof‐de Julio, Inti Zlobec, Jörn Dengjel, Bruce E. Torbett, Mario P. Tschan   +13 more
wiley   +1 more source

Assessing perceived needs for telepathology implementation in Colombia: a baseline study from Red GLORIA. [PDF]

Front Digit Health
Gomez-Suarez M, Acelas-Gonzalez GE, Mosquera-Zamudio A, Riaño-Moreno JC, Guerron-Gomez G, Camila Restrepo-Guarnizo M, Parra-Medina R.   +6 more
europepmc   +1 more source

Weakening the nuclear envelope: Lamin B receptor in melanoma metastasis

Molecular Oncology, EarlyView.
LBR‐driven nuclear fragility supports melanoma invasion. A: Melanocyte presents low LBR (Lamin B Receptor) levels, maintaining nuclear integrity and lamina‐chromatin tethering. B: During malignant progression, upregulation of LBR clusters at the INM (Inner Nuclear Membrane) during confined migration causes local lamina weakening and cholesterol ...
Francesca Lorenzini, Maria Caterina Mione   +1 more
wiley   +1 more source

Scientific and operational maturity of CE-MS: are we close? [PDF]

Trends Biotechnol
Wang D.
europepmc   +1 more source

Patient therapy outcome modeling in cancer organoids is improved by cancer‐associated fibroblasts and organoid assembly convolution

Molecular Oncology, EarlyView.
Patient‐derived organoids (PDOs) from pancreatic, colorectal, and gastric cancers were used to evaluate standard and experimental therapies. Incorporating cancer‐associated fibroblasts (CAFs) into organoid cultures improved patient therapy outcome prediction.
Marcin Grochowski, Liudmyla Dolinchuk, Michał Jerzak, Albert Gandurski, Tomasz Grochowski, Weronika Wojtyś, Maciej Zadrożny, Wojciech Kaźmierczak, Małgorzata Lenarcik, Marta Matejak‐Górska, Radosław Samsel, Tomasz Olesiński, Dawid Walerych   +12 more
wiley   +1 more source

Analytical Imprecision and Reference Change Values for Longitudinal Monitoring of NCD-Related Biochemical Analytes. [PDF]

Diagnostics (Basel)
Ahmad Ridzuan SN, Zamre MN, Shaari F, Anuar AAI, Hassan NH, Hamzan NI.   +5 more
europepmc   +1 more source

Loss of proton‐sensing TDAG8 increases tumor progression in mouse models of colon cancer

Molecular Oncology, EarlyView.
Loss of the pH‐sensing receptor TDAG8 accelerates colorectal cancer progression in mice. Animals lacking TDAG8 expression had increased tumor growth, DNA damage, and recruitment of tumor‐associated immune cells, including macrophages, neutrophils, and monocytes.
Ermanno Malagola, Yasmine Illi, Anna Bircher, Marijn Wilmink, Rachele F. Malagutti, Solenn Ottié, Cordelia Schuler, Pedro A. Ruiz, Cheryl de Vallière, Klaus Seuwen, Gerhard Rogler, Martin Hausmann   +11 more
wiley   +1 more source

Mapping Echocardiographic Practice in Emilia-Romagna: A Regional Healthcare Census. [PDF]

J Clin Med
Barbieri A, Mantovani F, Bursi F, Malaguti M, Fortuni F, Moderato L, Bartolacelli Y, Binno S, Malagoli A, Pavasini R, Pedone C, Suma S, Squeri A, Albini A, Vermi AC, Di Giannuario G, Laurito M, Li Calzi M, Navazio A, Moreo A, Di Salvo G, Carerj S.   +21 more
europepmc   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source